The Latest Analyst Ratings for Integra Lifesciences
Portfolio Pulse from Benzinga Insights
Integra Lifesciences (NASDAQ:IART) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, 3 indifferent, and 1 somewhat bearish. The average price target is $48.67, representing an upside from the current price of $42.5. However, this average represents a 13.09% decrease from the previous average price target of $56.00.
August 24, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a decreased price target could lead to uncertainty for Integra Lifesciences.
The mixed analyst ratings indicate that there is no clear consensus on the performance of Integra Lifesciences. The decrease in the average price target could also lead to uncertainty among investors, potentially impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100